MedTrace Logo

Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection

NCT00397709 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2008-12-31

No results posted yet for this study

Summary

The objective of the study was to compare the compliance and the side effects of a short course to treatment of latent tuberculosis infection during 3 months(isoniazid plus rifampin)group I, with the standard course for 6 months(isoniazid)group II .Prospective, comparative, randomized and open trial of patients with positive TST and the suitable criteria for treatment, in accordance with the guidelines of the CDC, excluding HIV infection. 105 patients were included. In Conclusion, a short course with isoniazid plus rifampin during 3 months shown better compliance with a lower percentage of abandonment that the course 6H. Tolerance is similar in the two courses.

Conditions

Interventions

DRUG

I ( isoniazid), II (isoniazid + rifampin )

Sponsors & Collaborators

  • Hospital Virgen de la Luz

    lead OTHER

Principal Investigators

  • Maria Paloma Geijo Martinez, MD · Unidad MI-Infecciosas. Hospital Virgen de la Luz. Cuenca 16002 Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-03-31
Completion
2006-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397709 on ClinicalTrials.gov